Acute Kidney Injury in Patients Hospitalized With COVID-19

March 26, 2020 updated by: Zhenhua Zen

Acute Kidney Injury in Patients Hospitalized With COVID-19 in Wuhan, China: a Single-center Retrospective Observational Study

The kidney may be affected in coronavirus-2019 disease (COVID-19). This study assessed the predictors and outcomes of acute kidney injury (AKI) among individuals with COVID-19.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

287

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hubei
      • Wuhan, Hubei, China, 430000
        • Hankou Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients admitted to Hankou Hospital in Wuhan with confirmed COVID-19 pneumonia from 5th Jan to 28th Feb.

Description

Inclusion Criteria:

  • COVID-19 pneumonia patients diagnosed by WHO criteria

Exclusion Criteria:

  • Patients who were younger than 18 years,
  • Patients who had undergone renal replacement therapy (RRT) before admission,
  • Patients whose entire stay lasted for less than 48 hours.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
AKI
COVID-19 patients with acute kidney injury
non-AKI
COVID-19 patients without acute kidney injury

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of Acute Kidney Injury
Time Frame: From date of admission until the date of discharge or death from any cause, up to 60 days
the incidence of Acute Kidney Injury
From date of admission until the date of discharge or death from any cause, up to 60 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the length of hospital stay
Time Frame: From date of admission until the date of discharge or death from any cause, up to 60 days
days from admission to discharge or death
From date of admission until the date of discharge or death from any cause, up to 60 days
Rate of Death
Time Frame: From date of admission until the date of death from any cause, up to 60 days
death from any cause in the hospital
From date of admission until the date of death from any cause, up to 60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zhenhua Zen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 26, 2020

Primary Completion (Actual)

February 28, 2020

Study Completion (Actual)

March 8, 2020

Study Registration Dates

First Submitted

March 17, 2020

First Submitted That Met QC Criteria

March 19, 2020

First Posted (Actual)

March 20, 2020

Study Record Updates

Last Update Posted (Actual)

March 30, 2020

Last Update Submitted That Met QC Criteria

March 26, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • hkyy2020-005 AKI

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe